ORIGINAL ARTICLE

Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in extremely preterm infants

A Trotter¹, L Maier², M Kron³, F Pohlandt¹

¹ Section of Neonatology and Pediatric Critical Care Medicine, Children’s Hospital, University of Ulm, Ulm, Germany
² Pharmacy, University of Ulm
³ Department of Biometry and Medical Documentation, University of Ulm

Correspondence to:
A Trotter
Center for Perinatal Medicine, Children’s Hospital, University of Bonn, Sigmund-Freudstr 25, 53105 Bonn, Germany; andreas.trotter{at}web.de

Objective: To study whether postnatal replacement of oestradiol and progesterone may help to prevent bronchopulmonary dysplasia (BPD).

Methods: This randomised placebo-controlled double-blind study enrolled 83 infants of <29 weeks gestational age and 1000 g birth weight requiring mechanical ventilation within 12 h after birth. Oestradiol (2.5 mg/kg/day) and progesterone (22.5 mg/kg/day) were given by continuous intravenous infusion of a standard lipid emulsion (15 ml/kg/day) in the replacement group (ESTRA-PRO). The placebo group received the same lipid emulsion without oestradiol or progesterone. A replacement period of at least 2 weeks but not >4 weeks was strived for and defined as "according to protocol". The primary outcome variable was the incidence of BPD or death.

Results: The median birth weight was 670 g (min–max 400–990 g) and the gestational age 25 weeks (23.1–28.1 weeks). The incidence of BPD or death was 48% in the placebo group and 44% in the ESTRA-PRO group (p = 0.38, one-sided testing, intention to treat analysis). In infants treated according to protocol, 32% (9 of 28) in the placebo group and 14% (3 of 21) in the ESTRA-PRO group developed BPD (p = 0.08).

Conclusion: Replacement of oestradiol and progesterone was not effective for prevention of BPD or death in extremely preterm born infants. Better-powered trials are needed to evaluate this new approach.

Abbreviations: ATP, according to protocol; BPD, bronchopulmonary dysplasia; ESTRA-PRO, oestradiol and progesterone replacement; ITT, intention to treat; ROP, retinopathy of prematurity; VEGF, vascular endothelial growth factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Fantoms

Martin Ward Platt
Arch. Dis. Child. Fetal Neonatal Ed. 2007 92: F79. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Lenney, W., Boner, A. L., Bont, L., Bush, A., Carlsen, K-H., Eber, E., Fauroux, B., Gotz, M., Greenough, A., Grigg, J., Hull, J., Kimpen, J., Sanchez Luna, M., de Benedictis, F. M. (2009). Medicines used in respiratory diseases only seen in children. Eur Respir J 34: 531-551 [Abstract] [Full Text]  
• McCurnin, D. C., Pierce, R. A., Willis, B. C., Chang, L. Y., Yoder, B. A., Yuhanna, I. S., Ballard, P. L., Clyman, R. I., Waleh, N., Maniscalco, W., Crapo, J. D., Grubb, P. H., Shaul, P. W. (2009). Postnatal Estradiol Up-regulates Lung Nitric Oxide Synthases and Improves Lung Function in Bronchopulmonary Dysplasia. Am. J. Respir. Crit. Care Med. 179: 492-500 [Abstract] [Full Text]